Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037395 | 0.98 | KMT2A (0.47) | KMT2ATAAR1RAB9AGAACES2 | |
| SCHEMBL6981241 | 0.82 | RAB9A (0.41) | KMT2ARAB9ANPC1L3MBTL1 | |
| SCHEMBL7342304 | 0.82 | BTK (0.39) | KMT2ATAAR1MAPT | |
| SCHEMBL27702200 | 0.80 | KMT2A (0.40) | KMT2AIDO1 | |
| SCHEMBL6037444 | 0.80 | KMT2A (0.46) | KMT2ATAAR1GAAMAPTSMN1; SMN2 | |
| SCHEMBL31752166 | 0.80 | NPC1 (0.54) | RAB9AGAACES1NPC1SMN1; SMN2 | |
| SCHEMBL29938710 | 0.79 | CYP26A1 (0.46) | KMT2ARAB9AGAAAKR1B1NPC1 | |
| SCHEMBL2421709 | 0.78 | KMT2A (0.42) | KMT2ATAAR1RAB9ANPC1MAPT | |
| SCHEMBL7341367 | 0.78 | CYP2D6 (0.35) | KMT2ATAAR1RAB9AGAACES1 | |
| SCHEMBL11211322 | 0.78 | TAAR1 (0.47) | KMT2ATAAR1RAB9AGAACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090011-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-6410534-B1 | ANTICANCER AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| US-20020022633-A1 | Inhibitors of prenyl-protein transferase | WILLIAMS THERESA M (US) | 2002-02-21 | — | — | US | disclosed |
| WO-2002002108-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1090011-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000001701-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | KMT2A 1240/4885TAAR1 4758/4885RAB9A 2619/4885 |
| US-20020022633-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, FNTB | KMT2A 2088/4885TAAR1 4813/4885RAB9A 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.